RVMD Revolution Medicines shares drop 57 after widerthanexpected loss no revenue reported in Q1 2026 BNAI BrandEngNet Q3 2025 EPS tops analyst estimates by a wide margin yet shares fall 05 today Gilead Sciences Inc GILD Schedules Participation at Four Leading Q2 2026 Healthcare Investor Conferences to Update Stakeholders on Pipeline and Operational Milestones FNV FrancoNevada reports 99 percent Q4 2025 EPS beat yet shares drop 169 percent in todays session